IP Library Granted Patent US 9,095,511
Granted Patent B2
US 9,095,511 · App. 12/739,873 · Granted Aug 4, 2015

Stabilization of oily suspensions comprising hydrophobic silicas

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,095,511
App. No.
12/739,873
Granted
Aug 4, 2015
Kind
B2
Abstract

The invention relates to a stabilization of fluid oil-based suspensions comprising a hydrophobic silica, and medicaments based on such suspensions.

Claims (14)

1. A method for stabilizing a fluid oil-based suspension comprising an active pharmaceutical ingredient and a hydrophobic silica against sedimentation, the method comprising contacting the hydrophobic silica with an amphiphilic substance comprising a nonionic polyoxyethylated compound in the fluid oil-based suspension, wherein the polyoxyethylated compound is selected from the group consisting of poloxamers, polyoxyethylene fatty acid glycerides, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acids, and polyoxyethylene fatty alcohols, and wherein the stabilized fluid oil-based suspension, following contact with the amphiphilic substance, comprises the amphiphilic substance in a proportion of 0.001-0.15% by weight.

2. The method according to claim 1 , wherein the active ingredient is a fluoroquinolone.

3. The method according to claim 2 , wherein the fluoroquinolone is enrofloxacin.

4. The method according to claim 2 , wherein the fluoroquinolone is pradofloxacin.

5. The method according to claim 2 , wherein the fluoroquinolone is marbofloxacin.

6. The method according to claim 2 , further comprising an antimycotic.

7. The method according to claim 6 , wherein the antimycotic is selected from the group consisting of clotrimazole, miconazole and bifonazole.

8. The method according to claim 2 , further comprising a corticoid.

9. The method according to claim 8 , wherein the corticoid is selected from the group consisting of dexamethasone, betamethasone and triamcinolone.

10. The method according to claim 1 , wherein the active ingredient is a triazine.

11. The method according to claim 1 , wherein the fluid oil-based suspension comprises the hydrophobic silica in a proportion of 0.15-4.0% by weight.

12. The method according to claim 1 , wherein the stabilized fluid oil-based suspension, following contact with the amphiphilic substance, comprises the amphiphilic substance in a proportion of 0.01-0.07% by weight.

13. The method according to claim 1 , wherein the stabilized fluid oil-based suspension, following contact with the amphiphilic substance, comprises the amphiphilic substance in a proportion of 0.005-0.09% by weight.

14. The method according to claim 1 , wherein the stabilized fluid oil-based suspension, following contact with the amphiphilic substance, comprises the amphiphilic substance in a proportion of 0.005-0.08% by weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2013
From: BAYER ANIMAL HEALTH GMBH
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030127/0549 →